A study to evaluate the role of zinc sulphate as analgesic in acute herpes zoster
Not Applicable
Completed
- Conditions
- Health Condition 1: B029- Zoster without complications
- Registration Number
- CTRI/2022/08/044798
- Lead Sponsor
- Pt BD Sharma University of health and science PGIMS Rohtak Haryana
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 48
Inclusion Criteria
: Patients of age group > 18 years of either sex referred to Pain
Clinic from Skin OPD after establishing the diagnosis of acute herpes zoster infection (fever,
pain and maculo-papular/vesicular rash), presenting within first week of acute phase and
willing to participate in the study will be included in this study.
Exclusion Criteria
1.Patients with any other cause of fever
2.any history of severe medical illness (i.e. cardiac diseases, diabetes mellitus, liver
disease, renal disease, CNS disorders)
3.Pregnant and lactating females
4. 4.Already taking any kind of zinc supplement, antiviral or analgesic other than standardized treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method VAS score, pre and post administration of oral zinc <br/ ><br>sulphate tablet in patients with acute herpes zosterTimepoint: T0: at time of presentation <br/ ><br>T1: at end of first week of acute herpes zoster <br/ ><br>T2: at end of second week of acute herpes zoster <br/ ><br>T3:at end of third week of acute herpes zoster <br/ ><br>T4: at end of fourth week of acute herpes zoster
- Secondary Outcome Measures
Name Time Method note and treat side effects of oral zinc sulphate, if any <br/ ><br>Timepoint: T0: at time of presentation <br/ ><br>T1: at end of first week of acute herpes zoster <br/ ><br>T2: at end of second week of acute herpes zoster <br/ ><br>T3:at end of third week of acute herpes zoster <br/ ><br>T4: at end of fourth week of acute herpes zoster